Rigel Pharmaceuticals, Inc. (RIGL) Thursday announced that it has entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc. resolving patent litigation related to Rigel's product Tavalisse (fostamatinib disodium hexahydrate).
The litigation resulted from submission by Annora of an Abbreviated New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of Tavalisse in the United States.
Under the terms of the settlement agreement, Annora will have a license to sell its generic product in second quarter of 2032 or earlier under certain circumstances.
In accordance with the agreement, the parties terminated all ongoing litigation between Rigel and Annora regarding Tavalisse patents pending in New Jersey.
https://www.nasdaq.com/articles/rigel-pharma-settles-tavalisse-patent-litigation-annora-pharma
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.